Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial

Clinical Therapeutics

Volumn 27, Issue 8, 2005, Pages 1164-1180

  Vinik, Aaron I ^a   Bril, Vera ^b   Kempler, Peter ^c   Litchy, William J ^d   Tesfaye, Solomon ^e   Price, Karen L ^f   Bastyr III, Edward J ^f,g  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d MAYO CLINIC   (United States)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^f ELI LILLY AND COMPANY   (United States)

^g INDIANA UNIVERSITY   (United States)

Author keywords

Adverse events; Clinical trials; Diabetic peripheral neuropathy; Phase II; Ruboxistaurin

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; PLACEBO; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DEMOGRAPHY; DIABETIC KETOACIDOSIS; DIABETIC NEUROPATHY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LEG EDEMA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVE CONDUCTION; NERVE POTENTIAL; NEUROLOGIC EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SAFETY; SCORING SYSTEM; SINUSITIS; STATISTICAL SIGNIFICANCE; SURAL NERVE; SYMPTOMATOLOGY; UPPER RESPIRATORY TRACT INFECTION; VIBRATION; VOMITING;

ADULT; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MALE; MALEIMIDES; MIDDLE AGED; PROTEIN KINASE C;

EID: 25844459952     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.08.001     Document Type: Article

References (79)

1. [published correction appears in Neurology. 1993;43:2345] Dyck PJ, Kratz KM, and Karnes JL The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study Neurology 43 1993 817 824
2. Maser RE, Steenkiste AR, and Dorman JS Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study Diabetes 38 1989 1456 1461
3. Tesfaye S, Stevens LK, and Stephenson JM Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study Diabetologia 39 1996 1377 1384
4. Fedele D, Comi G, and Coscelli C the Italian Diabetic Neuropathy Committee A multicenter study on the prevalence of diabetic neuropathy in Italy Diabetes Care 20 1997 836 843
5. Young MJ, Boulton AJ, and MacLeod AF A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population Diabetologia 36 1993 150 154
6. Manes C, Papazoglou N, and Sossidou E Prevalence of diabetic neuropathy and foot ulceration: Identification of potential risk factors - a population-based study Wounds 14 2002 11 15
7. Reiber GE, Pecoraro RE, and Koepsell TD Risk factors for amputation in patients with diabetes mellitus. A case-control study Ann Intern Med 117 1992 97 105
8. Adler AI, Boyko EJ, Ahroni JH, and Smith DG Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers Diabetes Care 22 1999 1029 1035
9. [published correction appears in Lancet. 1999;354:602] UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
10. The DCCT Research Group Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT) Diabetes 37 1988 476 481
11. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
12. Dyck PJ, Davies JL, and Wilson DM Risk factors for severity of diabetic polyneuropathy: Intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort Diabetes Care 22 1999 1479 1486
13. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT) Diabetologia 41 1998 416 423
14. Gaede P, Vedel P, and Larsen N Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
15. Boulton AJ, Vinik AI, Arezzo JC the American Diabetes Association Diabetic neuropathies: A statement by the American Diabetes Association Diabetes Care 28 2005 956 962
16. Sima AA, and Laudadio C Design of controlled clinical trials for diabetic polyneuropathy Semin Neurol 16 1996 187 191
17. Arezzo JC New developments in the diagnosis of diabetic neuropathy Am J Med 107 1999 9S 16S
18. Albers JW, Brown MB, Sima AA, Greene DA, and the Early Diabetes Intervention Trial Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: The effects of age, sex, type of diabetes, disease duration, and anthropometric factors Neurology 46 1996 85 91
19. Sundkvist G, Armstrong FM, and Bradbury JE the United Kingdom/Scandinavian Ponalrestat Trial Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months J Diabetes Complications 6 1992 123 130
20. American Diabetes Association American Academy of Neurology. Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy Diabetes Care 11 1988 592 597
21. Vinik AI, Suwanwalaikorn S, and Stansberry KB Quantitative measurement of cutaneous perception in diabetic neuropathy Muscle Nerve 18 1995 574 584
22. Dyck PJ, Bushek W, and Spring EM Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy Diabetes Care 10 1987 432 440
23. Malik RA, Newrick PG, and Sharma AK Microangiopathy in human diabetic neuropathy: Relationship between capillary abnormalities and the severity of neuropathy Diabetologia 32 1989 92 102
24. Giannini C, and Dyck PJ Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity Ann Neurol 37 1995 498 504
25. Izzo KL, Sobel E, Berney S, and Demopoulos JT Distal sensory nerves of the lower extremity in peripheral neuropathy: Comparison of medial dorsal cutaneous and sural nerve abnormalities Arch Phys Med Rehabil 66 1985 7 10
26. Izzo KL, Sobel E, and Demopoulos JT Diabetic neuropathy: Electrophysiologic abnormalities of distal lower extremity sensory nerves Arch Phys Med Rehabil 67 1986 7 11
27. Killian JM, and Foreman PJ Clinical utility of dorsal sural nerve conduction studies Muscle Nerve 24 2001 817 820
28. Shin JB, Seong YJ, and Lee HJ The usefulness of minimal F-wave latency and sural/radial amplitude ratio in diabetic polyneuropathy Yonsei Med J 41 2000 393 397
29. Behse F, and Buchthal F Sensory action potentials and biopsy of the sural nerve in neuropathy Brain 101 1978 473 493
30. Vinik A, Tesfaye S, Zhang D, Bastyr E the MBBQ Study Group LY333531 treatment improves diabetic peripheral neuropathy (DPN) with symptoms Diabetes 51 Suppl 2 2002 A79
31. Bril V, Vinik AI, Litchy WJ the MBBQ Study Group Detectable sural nerve action potential (SNAP) identifies patients with early diabetic peripheral neuropathy (DPN) Diabetes 51 Suppl 2 2002 A197
32. Cameron NE, and Cotter MA Metabolic and vascular factors in the pathogenesis of diabetic neuropathy Diabetes 46 Suppl 2 1997 S31 S37
33. Ways DK, and Sheetz MJ The role of protein kinase C in the development of the complications of diabetes Vitam Horm 60 2000 149 193
34. Bullock WH, Magnuson SR, and Choi S Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications Curr Top Med Chem 2 2002 915 938
35. Ishii H, Jirousek MR, and Koya D Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor Science 272 1996 728 731
36. Cotter MA, Jack AM, and Cameron NE Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes Clin Sci (Lond) 103 2002 311 321
37. Cameron NE, Eaton SE, Cotter MA, and Tesfaye S Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy Diabetologia 44 2001 1973 1988
38. Ozaki H, Yasuda K, and Kim YS Possible role of the protein kinase C/CPI-17 pathway in the augmented contraction of human myometrium after gestation Br J Pharmacol 140 2003 1303 1312
39. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/e/ policy/b3.htm. Accessed July 2005.
40. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice Guideline: Consolidated Guideline 1997 Health Canada, Therapeutic Products Programme Ottawa, Ont
41. Dyck PJ, Davies JL, Litchy WJ, and O'Brien PC Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort Neurology 49 1997 229 239
42. Goto Y, Hotta N, and Shigeta Y A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy Diabet Med 10 Suppl 2 1993 39S 43S
43. Dyck PJ, Turner DW, Davies JL the rhNGF Group Electronic case-report forms of symptoms and impairments of peripheral neuropathy Can J Neurol Sci 29 2002 258 266
44. Bastyr EJ, Zhang D, Bril V the MBBQ Study Group Neuropathy Total Symptom Score-6 questionnaire (NTSS-6) is a valid instrument for assessing the positive symptoms of diabetic peripheral neuropathy (DPN) Diabetes 51 Suppl 2 2002 A199
45. Bastyr EJ III, Price KL, Bril V the MBBQ Study Group Development and validity testing of the Neuropathy Total Symptom Score-6: Questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy Clin Ther 27 2005 1278 1294
46. Guy W ECDEU Assessment Manual for Psychopharmacology 1976 National Institute of Mental Health Rockville, Md
47. Apfel SC, Asbury AK, and Bril V the Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials J Neurol Sci 189 2001 3 5
48. Vinik AI, Bril V, Litchy WJ, et al, for the MBBQ Study Group. Sural nerve action potential identifies diabetic peripheral neuropathy responders. Muscle Nerve. In press.
49. Pfeifer MA, and Schumer MP Clinical trials of diabetic neuropathy: Past, present, and future Diabetes 44 1995 1355 1361
50. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care 20 1997 1183 1197
51. World Health Organization WHO Expert Committee on Diabetes Mellitus 2nd ed. 1980 WHO Geneva, Switzerland
52. [published correction appears in Neurology. 2001;56:1124] Greene DA, Arezzo JC, Brown MB the Zenarestat Study Group Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy Neurology 53 1999 580 591
53. Dyck PJ Detection, characterization, and staging of polyneuropathy: Assessed in diabetics Muscle Nerve 11 1988 21 32
54. Dyck PJ, Litchy WJ, and Lehman KA Variables influencing neuropathic endpoints: The Rochester Diabetic Neuropathy Study of Healthy Subjects Neurology 45 1995 1115 1121
55. Tesfaye S, Chaturvedi N, Eaton SE the EURODIAB Prospective Complications Study Group Vascular risk factors and diabetic neuropathy N Engl J Med 352 2005 341 350
56. Dyck PJ, O'Brien PC, and Kosanke JL A 4, 2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation threshold Neurology 43 1993 1508 1512
57. The DCCT Research Group Epidemiology of severe hypoglycemia in the diabetes control and complications trial Am J Med 90 1991 450 459
58. Dyck PJ, Zimmerman IR, and O'Brien PC Introduction of automated systems to evaluate touch-pressure, vibration, and thermal cutaneous sensation in man Ann Neurol 4 1978 502 510
59. Forst T, Nguyen M, and Forst S Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device Diabetes Nutr Metab 17 2004 163 168
60. Ziegler D, Hanefeld M, and Ruhnau KJ Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study) Diabetologia 38 1995 1425 1433
61. Dudewicz EJ, and Mishra SN Modern Mathematical Statistics 1988 Wiley New York, NY
62. Melzack R The McGill Pain Questionnaire: Major properties and scoring methods Pain 1 1975 277 299
63. Laudadio C, Sima AA the Ponalrestat Study Group Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial J Diabetes Complications 12 1998 121 127
64. Steiness I Vibratory perception in diabetics: A biothesiometric study Acta Med Scand 158 1957 327 335
65. Steiness I Vibratory perception in normal subjects: A biothesiometric study Acta Med Scand 158 1957 315 325
66. Resnick HE, Vinik AI, and Schwartz AV Independent effects of peripheral nerve dysfunction on lower-extremity physical function in old age: The Women's Health and Aging Study Diabetes Care 23 2000 1642 1647
67. Menz HB, Lord SR, St George R, and Fitzpatrick RC Walking stability and sensorimotor function in older people with diabetic peripheral neuropathy Arch Phys Med Rehabil 85 2004 245 252
68. Richardson JK, Thies SB, DeMott TK, and Ashton-Miller JA A comparison of gait characteristics between older women with and without peripheral neuropathy in standard and challenging environments J Am Geriatr Soc 52 2004 1532 1537
69. Resnick HE, Stansberry KB, and Harris TB Diabetes, peripheral neuropathy, and old age disability Muscle Nerve 25 2002 43 50
70. Vinik AI Diagnosis and management of diabetic neuropathy Clin Geriatr Med 15 1999 293 320
71. Cavanagh PR, Derr JA, and Ulbrecht JS Problems with gait and posture in neuropathic patients with insulin-dependent diabetes mellitus Diabet Med 9 1992 469 474
72. Bernstein RK Physical signs of the intrinsic minus foot Diabetes Care 26 2003 1945 1946
73. Boulton AJ, Malik RA, Arezzo JC, and Sosenko JM Diabetic somatic neuropathies Diabetes Care 27 2004 1458 1486
74. Coppini DV, Young PJ, and Weng C Outcome on diabetic foot complications in relation to clinical examination and quantitative sensory testing: A case-control study Diabet Med 15 1998 765 771
75. Russell JW, Karnes JL, and Dyck PJ Sural nerve myelinated fiber density differences associated with meaningful changes in clinical and electrophysiologic measurements J Neurol Sci 135 1996 114 117
76. Aiello LP, Bursell SE, and Devries T Amelioration of abnormal retinal hemodynamics by a protein kinase C beta selective inhibitor (LY333531) in patients with diabetes: Results of a phase 1 safety and pharmacodynamic clinical trial Invest Ophthalmol Vis Sci 40 1999 S192
77. Beckman JA, Goldfine AB, and Garrett L Protein kinase C inhibition potentiates vasodilation in hyperglycemia in healthy humans Circulation 102 Suppl 18 2000 II188
78. Abstract Ways K, Bursell S, and Devries T Amelioration of retinal hemodynamic dysfunction using a protein kinase C beta inhibitor in patients with diabetes Diabetologia 42 Suppl 1 1999 A12
79. Beckman JA, Goldfine AB, and Gordon MB Inhibition of protein kinase C beta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans Circ Res 90 2002 107 111